Company Insights

MTVA supplier relationships

Explore interactive graphBrowse insights index
MTVA supplier relationship map

MetaVia (MTVA) — Supplier relationships map and strategic implications for investors

MetaVia is a clinical-stage biotech that monetizes through licensing, clinical development, and the future commercialization of two licensed therapeutics (DA-1241 and DA-1726). The company’s near-term value is driven by clinical progress, intellectual property licensed from Dong‑A, and targeted collaborations that accelerate discovery and indication expansion; longer-term upside depends on successful regulatory milestones and commercial launch economics. Investors should treat MetaVia as a high‑upside, high‑dependency play: operating cash burn is evident, and several supplier and licensing relationships underpin both the pipeline and potential liabilities. For an on‑demand view of supplier exposure and disclosure trends, visit https://nullexposure.com/.

A quick operating snapshot investors need to know

MetaVia sources core drug assets and manufacturing capacity through an exclusive license and shared services arrangements, and partners with AI discovery and capital markets counterparties to advance programs and fund operations. The company is clinical-stage, has no revenue reported TTM, and is materially dependent on Dong‑A for licensed assets and manufacturing; parallel relationships with Syntekabio and financing banks support R&D and liquidity. This structure creates concentrated counterparty risk and outsized vendor importance relative to other small-cap biotech peers.

  • Contracting posture: Exclusive global license (excluding Korea) for two compounds; manufacturing and services tied to the licensor under a Shared Services Agreement.
  • Concentration & criticality: Dong‑A is both a major equity holder and the exclusive manufacturer/licensor of core assets — a single point of operational concentration.
  • Maturity: Programs are in early clinical stages (Phase 1 MAD data reported); revenue generation is future and milestone‑dependent.

For a consolidated supplier-risk view and tailored monitoring, see https://nullexposure.com/.

Catalog of disclosed supplier and related-party relationships

Below are all relationships disclosed in the source records, each followed by a concise, plain-English summary and the supporting reference.

Dong‑A — 2024 Form 10‑K (FY2024)

MetaVia states it works exclusively with Dong‑A as the sole manufacturer for the production of DA‑1241 and DA‑1726, establishing Dong‑A as the operational manufacturer for the core pipeline programs. Source: MetaVia FY2024 Form 10‑K filing (disclosed in the company’s FY2024 filings).

Dong‑A ST — PR Newswire corporate update (Q3 FY2025)

In the Q3 2025 earnings and corporate update, MetaVia disclosed R&D expenses related to investigational drug manufacturing and preclinical costs invoiced under a Shared Services Agreement with Dong‑A ST, noting direct costs of roughly $0.2 million in the three months ended September 30, 2025. Source: PR Newswire release reporting MetaVia third‑quarter 2025 financial results.

Syntekabio, Inc. — PR Newswire collaboration announcement (FY2025)

MetaVia announced a research collaboration with Syntekabio to identify additional targets and optimize DA‑1241’s therapeutic profile, leveraging AI‑driven discovery to expand indications beyond the current focus. Source: PR Newswire release, August 2025 collaboration announcement.

Ladenburg Thalmann & Co. Inc. — PR Newswire offering close (FY2026)

Ladenburg Thalmann acted as sole book‑running manager for MetaVia’s underwritten public offering, a capital markets relationship that provided immediate liquidity through a $9.3 million raise including the full exercise of the option. Source: PR Newswire release announcing closing of the underwritten public offering (FY2026).

Syntekabio, Inc. — PR Newswire modeling update (FY2026)

MetaVia provided an update that ongoing Syntekabio work produced positive AI‑modeling results using their DeepMatcher® platform, confirming therapeutic targets for vanoglipel and supporting the continued collaboration. Source: PR Newswire release reporting FY2026 modeling results from the Syntekabio collaboration.

Syntekabio, Inc. — PR Newswire Q3 2025 corporate update mention (FY2025)

The Q3 2025 corporate update also referenced the August 2025 Syntekabio agreement to explore indications beyond MASH and to optimize vanoglipel, reinforcing the multi‑period significance of the collaboration. Source: PR Newswire release included in MetaVia’s third‑quarter 2025 update.

Zacks SCR — Research disclosure (FY2025)

A Zacks coverage note on positive Phase 1 MAD data carried the customary disclosure that Zacks SCR received compensation from the issuer or related investor relations firms, indicating paid research coverage of MetaVia. Source: Zacks SCR article summarizing Phase 1 MAD DA‑1726 results (FY2025).

Dong‑A ST Co., Ltd. — PR Newswire patent portfolio release (FY2026)

MetaVia disclosed that its patent portfolio for DA‑1726 is exclusively licensed from Dong‑A ST Co., Ltd., providing protection through 2041, confirming the IP backbone is licensed and critical to future exclusivity. Source: PR Newswire release announcing global patent protection for DA‑1726 (FY2026).

Dong‑A ST Co. Ltd. — PR Newswire Phase 1 MAD top‑line release (FY2025)

In announcing Phase 1 MAD top‑line data for DA‑1726, MetaVia highlighted the importance of realizing the benefits of its license agreement with Dong‑A ST Co. Ltd. and the impact on future financial and operating results, underlining the commercial and financial linkage. Source: PR Newswire release with Phase 1 MAD top‑line data (FY2025).

Dong‑A ST Co. Ltd. — PR Newswire offering close disclosure (FY2026)

The offering close release reiterated the material nature of the license agreement with Dong‑A ST Co. Ltd. for MetaVia’s business outlook, tying capital raises to the company’s ability to realize licensed assets. Source: PR Newswire release about the underwritten public offering (FY2026).

Dong‑A ST Co. Ltd. — PR Newswire Syntekabio modeling release cross‑reference (FY2026)

The Syntekabio modeling update press release included language about how the license agreement with Dong‑A ST Co. Ltd. affects future financial and operating results, reflecting repeated corporate emphasis on that licensing relationship. Source: PR Newswire release about AI modeling results (FY2026).

What the disclosures imply for investors — practical constraints and risk signals

The disclosures collectively convey concentrated vendor and licensing dependence, specific cost commitments, and active collaborations that both de‑risk and concentrate program execution.

  • Exclusive licensing and manufacturing: MetaVia obtained an exclusive global license (ex‑Korea) and a Shared Services Agreement with Dong‑A that makes Dong‑A the licensor, manufacturer, and service provider for clinical supplies — this creates a single‑counterparty operational dependency (company‑level signal supported in filings referencing Dong‑A).
  • Materiality and financial exposure: Dong‑A’s equity ownership (noted as ~62% in filings) and contractual regulatory milestone exposure — up to $178m for DA‑1726 and $138m for DA‑1241 — represent material contingent liabilities tied to the license agreement (constraint evidence described in the 2022 License Agreement excerpts).
  • Active, multi‑year relationship: R&D spend under the Shared Services Agreement (reported at $4.9m in 2024) and payables to Dong‑A indicate an active relationship with ongoing cash flows and payables; milestone and royalty payment timelines create multi‑year dependency.
  • Complementary partnerships for discovery and capital: Syntekabio provides AI discovery services to broaden indications and optimize profiles, while investment banks like Ladenburg support liquidity events; these relationships reduce execution risk but do not remove the core dependency on the licensed IP and manufacturing.

Investment takeaway and next actions

MetaVia’s architecture is IP‑centric and vendor‑concentrated: shareholder returns depend on successful clinical development, milestone realizations to the licensor, and subsequent commercialization choices. Key investment risks are concentrated counterparty risk to Dong‑A, contingent milestone obligations, and the historical lack of revenue; key upside is the exclusive rights to potentially best‑in‑class therapeutics and accelerating AI collaborations.

For an investor or operator building a diligence checklist, focus on:

  • Contract terms and termination triggers with Dong‑A;
  • Milestone/royalty schedules and projected cash impact;
  • Data from ongoing Syntekabio modeling and clinical readouts.

To track supplier disclosure trends, additional filings, and structured supplier exposures for MetaVia and peers, visit https://nullexposure.com/. If you want an integrated supplier risk brief or a custom watchlist tied to MetaVia counterparties, request a tailored report at https://nullexposure.com/.